samedan logo
 
 
 
spacer
home > ebr > spring 2003 > omega-3 fatty acids in the prevention of myocardial infarction
PUBLICATIONS
European Biopharmaceutical Review

Omega-3 Fatty Acids in the Prevention of Myocardial Infarction

Atherosclerosis is an arterial disease causing myocardial infarction and stroke, angina pectoris and sudden death. Atherosclerosis is responsible for about 60 per cent of total mortality in the US and about 22 per cent of the population has one or more types of cardiovascular disease (1). Atherosclerosis is therefore the main threat to life and health in industrialised society today.

Sclerosis means hardening, but this pathological feature is common and in general accepted as a rather benign disease: a normal ageing of the artery. Pathologists recognise two different types of atherosclerotic plaques: large, firm plaques consisting of organised connective tissue and small, soft plaques containing lipids and inflammatory cells. The large sclerotic plaques are stable, hard structures not likely to disrupt normal function, but nevertheless show up clearly on the angiogram.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Morten Bryhn, Director of R&D at Pronova Biocare

Dr Morten Bryhn is a specialist in cardiology and internal medicine, holding a PhD and an Assistant Professorship in the field of cardiology.

Dr Bryhn currently serves as Director of R&D at Pronova Biocare and has published around 100 scientific articles, several of which deal with the effects of omega-3 fatty acids.
 

spacer
Dr Morten Bryhn
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

Using Device Strategy to Drive R&D Productivity

Phillips-Medisize


More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement